Jazz Pharmaceuticals (JAZZ) Operating Leases (2019 - 2026)

Jazz Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $47.3 million for Q1 2026.

• On a quarterly basis, Operating Leases rose 21.97% year-over-year to $47.3 million in Q1 2026; TTM through Mar 2026 was $47.3 million, a 21.97% increase from a year earlier, with the FY2025 full-year figure at $50.9 million, up 30.72% from the prior year.
• Operating Leases slipped to $47.3 million in Q1 2026 per JAZZ's latest filing, from $50.9 million in the prior quarter.
• Across five years, Operating Leases topped out at $83.1 million in Q1 2022 and bottomed at $38.8 million in Q1 2025.
• The 5-year median for Operating Leases is $61.9 million (2023), against an average of $61.4 million.
• Across the five-year window, Operating Leases slumped 50.28% in 2022 and surged 30.72% in 2025, its largest moves.
• Year by year, Operating Leases stood at $71.8 million in 2022, then retreated by 17.56% to $59.2 million in 2023, then tumbled by 34.25% to $38.9 million in 2024, then soared by 30.72% to $50.9 million in 2025, then decreased by 7.07% to $47.3 million in 2026.
• Per Business Quant, the three latest JAZZ Operating Leases figures stand at $47.3 million (Q1 2026), $50.9 million (Q4 2025), and $53.4 million (Q3 2025).